Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone64-7479-9828
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Aptose Biosciences (NASDAQ:APTO) Frequently Asked Questions
What is Aptose Biosciences' stock symbol?
Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."
How were Aptose Biosciences' earnings last quarter?
Aptose Biosciences Inc. (NASDAQ:APTO) announced its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.01. View Aptose Biosciences' Earnings History.
When is Aptose Biosciences' next earnings date?
What price target have analysts set for APTO?
6 brokerages have issued 12-month price objectives for Aptose Biosciences' stock. Their forecasts range from $5.00 to $6.00. On average, they expect Aptose Biosciences' stock price to reach $5.80 in the next twelve months. This suggests a possible upside of 194.4% from the stock's current price. View Analyst Price Targets for Aptose Biosciences.
What is the consensus analysts' recommendation for Aptose Biosciences?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptose Biosciences.
What are Wall Street analysts saying about Aptose Biosciences stock?
Here are some recent quotes from research analysts about Aptose Biosciences stock:
- 1. According to Zacks Investment Research, "Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. " (8/12/2019)
- 2. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We reiterate our Buy and $8.50 price target. Our target is based on our clinical net present value (NPV) model, which derives its value from both the CG-806 opportunity in AML and APTO-253 opportunity in AML and MDS. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (11/7/2018)
Has Aptose Biosciences been receiving favorable news coverage?
News coverage about APTO stock has been trending somewhat positive on Saturday, InfoTrie reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aptose Biosciences earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Aptose Biosciences.
Who are some of Aptose Biosciences' key competitors?
Some companies that are related to Aptose Biosciences include Tcr2 Therapeutics (TCRR), Prevail Therapeutics (PRVL), Agenus (AGEN), Avrobio (AVRO), Harpoon Therapeutics (HARP), Precision BioSciences (DTIL), CASI Pharmaceuticals (CASI), Cellular Biomedicine Group (CBMG), Scholar Rock (SRRK), Gritstone Oncology (GRTS), BioCryst Pharmaceuticals (BCRX), PDL BioPharma (PDLI), Eiger Biopharmaceuticals (EIGR), ADMA Biologics (ADMA) and La Jolla Pharmaceutical (LJPC).
What other stocks do shareholders of Aptose Biosciences own?
Who are Aptose Biosciences' key executives?
Aptose Biosciences' management team includes the folowing people:
- Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)
- Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)
- Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical Operations
- Dr. Stephen B. Howell, Chief Medical Officer (Age 73)
- Mr. Peter Murray, Director of Clinical Devel.
How do I buy shares of Aptose Biosciences?
Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Aptose Biosciences' stock price today?
One share of APTO stock can currently be purchased for approximately $1.97.
How big of a company is Aptose Biosciences?
What is Aptose Biosciences' official website?
How can I contact Aptose Biosciences?
Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The biotechnology company can be reached via phone at 64-7479-9828 or via email at [email protected]
MarketBeat Community Rating for Aptose Biosciences (NASDAQ APTO)
MarketBeat's community ratings are surveys of what our community members think about Aptose Biosciences and other stocks. Vote "Outperform" if you believe APTO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTO will underperform the S&P 500 over the long term. You may vote once every thirty days.
